JPMorgan analyst James Gordon raised the firm’s price target on Argenx to EUR 500 from EUR 480 and keeps an Overweight rating on the shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARGX:
- Argenx included on Wells Fargo’s Tactical Ideas List for Q1 2023
- Wells Fargo upgrades Immunovant to Overweight, raises price target to $27
- argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
- Argenx price target raised to $478 from $471 at Stifel
- Piper recommends ‘down market cap’ biotech exposure for 2023
